Therefore, the potential use of PACAP/PAC1 agonists as novel pharmacological agents in the treatment of appetite disorders, obesity and metabolic syndrome is promising and needs further exploration. This evidence concerns the gene ADCYAP1 and obesity due to melanocortin 4 receptor deficiency.